Evidence map›Paper›PMID 32718147›Full record

ArticleClinical and experimental pediatrics2020

Evaluating the effects of probiotics in pediatrics with recurrent abdominal pain.

Parisa Rahmani, Azin Ghouran-Orimi, Farzaneh Motamed, Alireza Moradzadeh

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 9 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 9 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Efficacy and Safety ofNutrients · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Probiotics in Functional Gastrointestinal Disorders.Advances in experimental medicine and biology · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. An Update on the Assessment and Management of Pediatric Abdominal Pain.Pediatric health, medicine and therapeutics · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Parisa RahmaniPediatric Gastroenterology and Hepatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Azin Ghouran-OrimiIran university of Medical Sciences, Tehran, Iran.
Farzaneh MotamedPediatric Gastroenterology and Hepatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Alireza MoradzadehDepartment of Pediatric Gastroenterology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRChildren's Medical Center · IRIran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecurrent abdominal pain (RAP) is one of the frequent complaints in general practice, particularly in pediatrics and is among the common cause of referral to gastroenterology clinics. PURPOSE: This study is designed to investigate the effects of probiotics for the treatment of RAP and desired therapeutic outcomes.

methodsOne hundred twenty-five children with the diagnosis of RAP according to Rome III criteria for irritable bowel syndrome (IBS), functional abdominal pain (FAP), functional dyspepsia (FD), and abdominal migraine (AM), were enrolled in this double-blind randomized controlled trial.

resultsSixty-five subjects received probiotics, and others received placebo treatment for 4 weeks. Lactobacillus reuteri was therapeutically effective in 32 patients compared to 8 patients, responding to the placebo treatment. Compared to baseline, all pain-related variables showed a significant reduction for the IBS and FD at the end of the 4th week. However, it did not respond well in FAP and AM groups. Pain-related outcomes such as, frequency of the pain, severity, and duration of the pain were decreased following the probiotic treatment. No therapeutic response was seen in AM group after the administration of probiotics. L. reuteri significantly led to pain relief in the overall population, and also in FAP, FD, and IBS subgroups.

conclusionL. reuteri probiotics are likely to lead to RAP relief and can be recommended for the treatment of functional gastrointestinal disorders.

Indexed as

ChildLactobacillus reuteriRecurrent abdominal pain

Identifiers

PMID32718147
PMCPMC7738771
OpenAlexW3043884600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.